Literature DB >> 18550858

Transcriptional repression of c-Myb and GATA-2 is involved in the biologic effects of C/EBPalpha in p210BCR/ABL-expressing cells.

Angela Rachele Soliera1, Maria Rosa Lidonnici, Giovanna Ferrari-Amorotti, Marco Prisco, Ying Zhang, Robert V Martinez, Nick J Donato, Bruno Calabretta.   

Abstract

Ectopic C/EBPalpha expression in p210(BCR/ABL)-expressing hematopoietic cells induces granulocytic differentiation, inhibits proliferation, and suppresses leukemogenesis. To assess the underlying mechanisms, C/EBPalpha targets were identified by microarray analyses. Upon C/EBPalpha activation, expression of c-Myb and GATA-2 was repressed in 32D-BCR/ABL, K562, and chronic myelogenous leukemia (CML) blast crisis (BC) primary cells but only c-Myb levels decreased slightly in CD34(+) normal progenitors. The role of these 2 genes for the effects of C/EBPalpha was assessed by perturbing their expression in K562 cells. Ectopic c-Myb expression blocked the proliferation inhibition- and differentiation-inducing effects of C/EBPalpha, whereas c-Myb siRNA treatment enhanced C/EBPalpha-mediated proliferation inhibition and induced changes in gene expression indicative of monocytic differentiation. Ectopic GATA-2 expression suppressed the proliferation inhibitory effect of C/EBPalpha but blocked in part the effect on differentiation; GATA-2 siRNA treatment had no effects on C/EBPalpha induction of differentiation but inhibited proliferation of K562 cells, alone or upon C/EBPalpha activation. In summary, the effects of C/EBPalpha in p210(BCR/ABL)-expressing cells depend, in part, on transcriptional repression of c-Myb and GATA-2. Since perturbation of c-Myb and GATA-2 expression has nonidentical consequences for proliferation and differentiation of K562 cells, the effects of C/EBPalpha appear to involve dif-ferent transcription-regulated targets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18550858      PMCID: PMC2518896          DOI: 10.1182/blood-2007-09-114975

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  E2F repression by C/EBPalpha is required for adipogenesis and granulopoiesis in vivo.

Authors:  B T Porse; X Xu; B Lindberg; U M Wewer; L Friis-Hansen; C Nerlov
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

2.  Multilineage transcriptional priming and determination of alternate hematopoietic cell fates.

Authors:  Peter Laslo; Chauncey J Spooner; Aryeh Warmflash; David W Lancki; Hyun-Jun Lee; Roger Sciammas; Benjamin N Gantner; Aaron R Dinner; Harinder Singh
Journal:  Cell       Date:  2006-08-25       Impact factor: 41.582

3.  C/EBPalpha binds and activates the PU.1 distal enhancer to induce monocyte lineage commitment.

Authors:  Christine Yeamans; Dehua Wang; Ido Paz-Priel; Bruce E Torbett; Daniel G Tenen; Alan D Friedman
Journal:  Blood       Date:  2007-08-01       Impact factor: 22.113

4.  Enhanced proliferative potential of hematopoietic cells expressing degradation-resistant c-Myb mutants.

Authors:  Francesca Corradini; Vincenzo Cesi; Viviana Bartella; Elisabetta Pani; Rita Bussolari; Olivia Candini; Bruno Calabretta
Journal:  J Biol Chem       Date:  2005-05-31       Impact factor: 5.157

5.  Leukemogenesis induced by wild-type and STI571-resistant BCR/ABL is potently suppressed by C/EBPalpha.

Authors:  Giovanna Ferrari-Amorotti; Karen Keeshan; Michela Zattoni; Clara Guerzoni; Giorgio Iotti; Sara Cattelani; Nick J Donato; Bruno Calabretta
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

6.  c-Myc is a critical target for c/EBPalpha in granulopoiesis.

Authors:  L M Johansen; A Iwama; T A Lodie; K Sasaki; D W Felsher; T R Golub; D G Tenen
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

7.  AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia.

Authors:  T Pabst; B U Mueller; N Harakawa; C Schoch; T Haferlach; G Behre; W Hiddemann; D E Zhang; D G Tenen
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

8.  High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Authors:  Ji Suk Chang; Ramasamy Santhanam; Rossana Trotta; Paolo Neviani; Anna M Eiring; Edward Briercheck; Mattia Ronchetti; Denis C Roy; Bruno Calabretta; Michael A Caligiuri; Danilo Perrotti
Journal:  Blood       Date:  2007-05-02       Impact factor: 22.113

Review 9.  Disruption of differentiation in human cancer: AML shows the way.

Authors:  Daniel G Tenen
Journal:  Nat Rev Cancer       Date:  2003-02       Impact factor: 60.716

10.  Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations.

Authors:  Hanna S Radomska; Daniela S Bassères; Rui Zheng; Pu Zhang; Tajhal Dayaram; Yukiya Yamamoto; David W Sternberg; Nathalie Lokker; Neill A Giese; Stefan K Bohlander; Susanne Schnittger; Marie-Hélène Delmotte; Roger J Davis; Donald Small; Wolfgang Hiddemann; D Gary Gilliland; Daniel G Tenen
Journal:  J Exp Med       Date:  2006-01-30       Impact factor: 14.307

View more
  9 in total

1.  Expression of the transcriptional repressor Gfi-1 is regulated by C/EBP{alpha} and is involved in its proliferation and colony formation-inhibitory effects in p210BCR/ABL-expressing cells.

Authors:  Maria Rosa Lidonnici; Alessandra Audia; Angela Rachele Soliera; Marco Prisco; Giovanna Ferrari-Amorotti; Todd Waldron; Nick Donato; Ying Zhang; Robert V Martinez; Tessa L Holyoake; Bruno Calabretta
Journal:  Cancer Res       Date:  2010-10-05       Impact factor: 12.701

2.  Targeting acute myeloid leukemia by drug-induced c-MYB degradation.

Authors:  V Walf-Vorderwülbecke; K Pearce; T Brooks; M Hubank; M M van den Heuvel-Eibrink; C M Zwaan; S Adams; D Edwards; J Bartram; S Samarasinghe; P Ancliff; A Khwaja; N Goulden; G Williams; J de Boer; O Williams
Journal:  Leukemia       Date:  2017-11-01       Impact factor: 11.528

3.  Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Marco De Dominici; Patrizia Porazzi; Angela Rachele Soliera; Samanta A Mariani; Sankar Addya; Paolo Fortina; Luke F Peterson; Orietta Spinelli; Alessandro Rambaldi; Giovanni Martinelli; Anna Ferrari; Ilaria Iacobucci; Bruno Calabretta
Journal:  Cancer Res       Date:  2017-12-12       Impact factor: 12.701

4.  Repression of cellular retinoic acid-binding protein II during adipocyte differentiation.

Authors:  Daniel C Berry; Hooman Soltanian; Noa Noy
Journal:  J Biol Chem       Date:  2010-03-12       Impact factor: 5.157

5.  c-Myb binds MLL through menin in human leukemia cells and is an important driver of MLL-associated leukemogenesis.

Authors:  Shenghao Jin; Huiwu Zhao; Yan Yi; Yuji Nakata; Anna Kalota; Alan M Gewirtz
Journal:  J Clin Invest       Date:  2010-01-19       Impact factor: 14.808

6.  GATA2 regulates dendritic cell differentiation.

Authors:  Koichi Onodera; Tohru Fujiwara; Yasushi Onishi; Ari Itoh-Nakadai; Yoko Okitsu; Noriko Fukuhara; Kenichi Ishizawa; Ritsuko Shimizu; Masayuki Yamamoto; Hideo Harigae
Journal:  Blood       Date:  2016-06-03       Impact factor: 22.113

Review 7.  The Philadelphia chromosome in leukemogenesis.

Authors:  Zhi-Jie Kang; Yu-Fei Liu; Ling-Zhi Xu; Zi-Jie Long; Dan Huang; Ya Yang; Bing Liu; Jiu-Xing Feng; Yu-Jia Pan; Jin-Song Yan; Quentin Liu
Journal:  Chin J Cancer       Date:  2016-05-27

8.  Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells.

Authors:  Manuela Spagnuolo; Giulia Regazzo; Marco De Dominici; Andrea Sacconi; Andrea Pelosi; Etleva Korita; Francesco Marchesi; Francesco Pisani; Alessandra Magenta; Valentina Lulli; Iole Cordone; Andrea Mengarelli; Sabrina Strano; Giovanni Blandino; Maria G Rizzo; Bruno Calabretta
Journal:  Haematologica       Date:  2018-08-03       Impact factor: 9.941

Review 9.  Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia.

Authors:  Patrizia Porazzi; Marco De Dominici; Joseph Salvino; Bruno Calabretta
Journal:  Genes (Basel)       Date:  2021-08-29       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.